Pfizer seeks Japan’s approval of vaccine for kids aged 5-11
November 10, 2021
TOKYO (Jiji Press) — U.S. pharmaceutical giant Pfizer Inc. and German biomedical company BioNTech SE said Wednesday they have applied to Japan’s health ministry for approval of their COVID-19 vaccine for children aged 5 to 11.
The vaccine has been authorized for emergency use for the age group in the United States. In Japan, it is currently approved for those aged 12 or older.
Clinical trials overseas have found that the vaccine is some 90% effective in preventing COVID-19 in children aged 5-11 with a dosage one-third of the amount given to adults, according to Pfizer.
The vaccine is safe to use for the younger children and side effects among them are comparable with those among adults, the company said.
Children tend to be less affected by the novel coronavirus, but they are encouraged to get shots in the United States to prevent them from transmitting the virus to others.
"SOCIETY" POPULAR ARTICLE
JN ACCESS RANKING
- Japan, Finland confirm unity in dealing with Russia
- Mangaka Fujiko Fujio A dies at 88
- China’s aircraft carrier drills near Japan aimed at around-the-clock attack capability
- Fukushima lab releases images of ‘highly likely’ UFOs
- As wheat prices soar, Japanese food industry pushes rice flour as alternative